[1]Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6):394-424.
[2]Fitzmaurice C, Dicker D, Pain A, et al. The Global Burden of Cancer 2013. JAMA Oncol, 2015, 1(4):505-27.
[3]Bai L, Liu Z, Fang Q, et al. The trends and projections in the incidence and mortality of liver cancer in urban Shanghai: a population-based study from 1973 to 2020. Clin Epidemiol, 2018, 10(277-288.
[4]Njei B, Rotman Y, Ditah I, et al. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology, 2015, 61(1):191-9.
[5]Chen X, Liu H P, Li M, et al. Advances in non-surgical management of primary liver cancer. World J Gastroenterol, 2014, 20(44):16630-8.
[6]Kitao H, Iimori M, Kataoka Y, et al. DNA replication stress and cancer chemotherapy. 2018, 109(2):264-271.
[7]Stiuso P, Potenza N, Lombardi A, et al. MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib. Mol Ther Nucleic Acids, 2015, 4(e233.
[8]Caraglia M, Giuberti G, Marra M, et al. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis, 2011, 2(4):e150.
[9]Lombardi A, Grimaldi A, Zappavigna S, et al. Hepatocarcinoma: genetic and epigenetic features. Minerva Gastroenterol Dietol, 2018, 64(1):14-27.
[10]Tomasetti C,Li L Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. 2017, 355(6331):1330-1334.
[11]Chang W H,Lai A G Transcriptional landscape of DNA repair genes underpins a pan-cancer prognostic signature associated with cell cycle dysregulation and tumor hypoxia. DNA Repair (Amst), 2019, 78(142-153.
[12]Tolan H K, Tozan-Beceren A, Sardas S, et al. DNA repair capacity of the colorectal cancer patients and the correlation between the pathological parameters. Niger J Clin Pract, 2019, 22(2):194-200.
[13]Damia G,Broggini M Platinum Resistance in Ovarian Cancer: Role of DNA Repair. 2019, 11(1):
[14]Chen X, Chen F, Ren Y, et al. IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2. 2019,
[15]Lopez-Camarillo C, Rincon D G, Ruiz-Garcia E, et al. DNA Repair Proteins as Therapeutic Targets in Ovarian Cancer. Curr Protein Pept Sci, 2019, 20(4):316-323.
[16]Wang R, Ye X H, Zhao X L, et al. Development of a five-gene signature as a novel prognostic marker in ovarian cancer. Neoplasma, 2018,
[17]Zheng T, Pang Z, Zhao Z A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Biosci Rep, 2019, 39(5):
[18]Wei H, Li J, Xie M, et al. Comprehensive analysis of metastasis-related genes reveals a gene signature predicting the survival of colon cancer patients. 2018, 6(e5433.
[19]Kim K, Jeon S, Kim T M, et al. Immune Gene Signature Delineates a Subclass of Papillary Thyroid Cancer with Unfavorable Clinical Outcomes. 2018, 10(12):
[20]Cai W, Li Y, Huang B, et al. Esophageal cancer lymph node metastasis-associated gene signature optimizes overall survival prediction of esophageal cancer. J Cell Biochem, 2019, 120(1):592-600.
[21]Zuo S, Dai G, Ren X Identification of a 6-gene signature predicting prognosis for colorectal cancer. Cancer Cell Int, 2019, 19(6.
[22]Sun L L, Wu J Y, Wu Z Y, et al. A three-gene signature and clinical outcome in esophageal squamous cell carcinoma. Int J Cancer, 2015, 136(6):E569-77.
[23]Gold B Somatic mutations in cancer: Stochastic versus predictable. Mutat Res, 2017, 814(37-46.
[24]Perduca V, Alexandrov L B, Kelly-Irving M, et al. Stem cell replication, somatic mutations and role of randomness in the development of cancer. 2019, 34(5):439-445.
[25]Nakajima Y,Kuribayashi K Adenosine Deaminase in Pleural Effusion and Its Relationship with Clinical Parameters in Patients with Malignant Pleural Mesothelioma. 2020, 38(6):356-364.
[26]Kong J, Wang T, Zhang Z, et al. Five Core Genes Related to the Progression and Prognosis of Hepatocellular Carcinoma Identified by Analysis of a Coexpression Network. DNA Cell Biol, 2019, 38(12):1564-1576.
[27]Xiang J, Fang L, Luo Y, et al. Levels of human replication factor C4, a clamp loader, correlate with tumor progression and predict the prognosis for colorectal cancer. J Transl Med, 2014, 12(320.
[28]Ying H, Xu Z, Chen M, et al. Overexpression of Zwint predicts poor prognosis and promotes the proliferation of hepatocellular carcinoma by regulating cell-cycle-related proteins. Onco Targets Ther, 2018, 11(689-702.
[29]Li N, Zhao L, Guo C, et al. Identification of a novel DNA repair-related prognostic signature predicting survival of patients with hepatocellular carcinoma. Cancer Manag Res, 2019, 11(7473-7484.
[30]Wu W, Liu H, Lei R, et al. Genetic variants in GTF2H1 and risk of lung cancer: a case-control analysis in a Chinese population. Lung Cancer, 2009, 63(2):180-6.
[31]Nastase A, Lupo A, Laszlo V, et al. Platinum Drug Sensitivity Polymorphisms in Stage III Non-small Cell Lung Cancer With Invasion of Mediastinal Lymph Nodes. Cancer Genomics Proteomics, 2020, 17(5):587-595.
[32]Prete S D, Montella L, Caraglia M, et al. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother Pharmacol, 2010, 66(5):837-44.
[33]Itzel T, Spang R, Maass T, et al. Random gene sets in predicting survival of patients with hepatocellular carcinoma. J Mol Med (Berl), 2019, 97(6):879-888.
[34]Lee J S, Chu I S, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology, 2004, 40(3):667-76.
[35]Poulos R C, Wong Y T, Ryan R Analysis of 7,815 cancer exomes reveals associations between mutational processes and somatic driver mutations. 2018, 14(11):e1007779.
[36]Levine A J, Puzio-Kuter A M, Chan C S, et al. The Role of the p53 Protein in Stem-Cell Biology and Epigenetic Regulation. Cold Spring Harb Perspect Med, 2016, 6(9):
[37]Herath N I, Devun F, Lienafa M C, et al. The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis. Mol Cancer Ther, 2016, 15(1):15-22.
[38]Yan J, Zhou C, Guo K, et al. A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma. J Cell Biochem, 2019, 120(1):213-223.
[39]Kancherla V, Abdullazade S, Matter M S, et al. Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma. Front Genet, 2018, 9(2.